Rep. Robert Bresnahan, Jr. Buys Bio-Techne Co. (NASDAQ:TECH) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Bio-Techne Stock Down 2.0 %

TECH stock traded down $1.22 during mid-day trading on Friday, reaching $58.73. 1,505,061 shares of the company traded hands, compared to its average volume of 1,111,228. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. The firm’s 50 day moving average price is $66.56 and its 200 day moving average price is $71.47. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of 59.32, a P/E/G ratio of 2.88 and a beta of 1.30. Bio-Techne Co. has a fifty-two week low of $56.60 and a fifty-two week high of $85.57.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. As a group, equities research analysts predict that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Monday, February 17th were issued a $0.08 dividend. The ex-dividend date was Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.54%. Bio-Techne’s dividend payout ratio is presently 32.32%.

Insider Activity

In other news, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $65.96, for a total transaction of $122,685.60. Following the sale, the director now owns 1,976 shares in the company, valued at approximately $130,336.96. This trade represents a 48.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the sale, the chief executive officer now owns 39,004 shares of the company’s stock, valued at approximately $3,014,619.16. The trade was a 25.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its position in Bio-Techne by 4.0% during the fourth quarter. California State Teachers Retirement System now owns 249,350 shares of the biotechnology company’s stock worth $17,961,000 after purchasing an additional 9,625 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new stake in shares of Bio-Techne during the fourth quarter worth $3,661,000. Siemens Fonds Invest GmbH purchased a new position in shares of Bio-Techne in the fourth quarter valued at $312,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Bio-Techne in the 4th quarter worth about $4,082,000. Finally, Jefferies Financial Group Inc. grew its holdings in Bio-Techne by 284.6% during the 4th quarter. Jefferies Financial Group Inc. now owns 52,244 shares of the biotechnology company’s stock valued at $3,763,000 after buying an additional 38,661 shares in the last quarter. Institutional investors own 98.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TECH. StockNews.com lowered shares of Bio-Techne from a “buy” rating to a “hold” rating in a research report on Wednesday. Citigroup dropped their target price on shares of Bio-Techne from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Baird R W lowered Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. KeyCorp lifted their price target on Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Finally, Scotiabank upped their price objective on Bio-Techne from $88.00 to $90.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 6th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.25.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.